retatrutide safety clinical trial results Retatrutide vs Ozempic: Trial Comparisons Lilly's triple agonist, retatrutide, delivered

Tirzepatide and semaglutide are generally safe, but they may not be suitable for everyone, including: People with a personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) People with a personal or family history of pancreatitis People with known hypersensitivity to any component of the medication People who are pregnant, breastfeeding, and planning to become pregnant Always consult a healthcare provider before starting a new medication

As a dietary supplement, it does not require FDA approval before sale

The former is currently awaiting FDA approval for a handful of oral, daily GLP-1 agonists, while the latter is developing combination therapies that use their muscle-preserving antibodies, trevogrumab and garetosmab, alongside GLP-1 drugs like Wegovy and Ozempic, to improve fat loss while preserving muscle mass

Meet Our Physicians Dr